Tags

Type your tag names separated by a space and hit enter

Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
Virol J. 2021 01 12; 18(1):16.VJ

Abstract

BACKGROUND

SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV. SARS-CoV-2 is highly pathogenic in humans and is classified as a biosafety level (BSL)-3 pathogen, which makes manipulating it relatively difficult due to its infectious nature.

METHODS

To circumvent the need for BSL-3 laboratories, an alternative assay was developed that avoids live virus and instead uses a recombinant VSV expressing luciferase and possesses the full length or truncated spike proteins of SARS-CoV-2. Furthermore, to measure SARS-CoV-2 neutralizing antibodies under BSL2 conditions, a chemiluminescence reduction neutralization test (CRNT) for SARS-CoV-2 was developed. The neutralization values of the serum samples collected from hospitalized patients with COVID-19 or SARS-CoV-2 PCR-negative donors against the pseudotyped virus infection evaluated by the CRNT were compared with antibody titers determined from an enzyme-linked immunosorbent assay (ELISA) or an immunofluorescence assay (IFA).

RESULTS

The CRNT, which used whole blood collected from hospitalized patients with COVID-19, was also examined. As a result, the inhibition of pseudotyped virus infection was specifically observed in both serum and whole blood and was also correlated with the results of the IFA.

CONCLUSIONS

In conclusion, the CRNT for COVID-19 is a convenient assay system that can be performed in a BSL-2 laboratory with high specificity and sensitivity for evaluating the occurrence of neutralizing antibodies against SARS-CoV-2.

Authors+Show Affiliations

Department of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan. toyamaeiken3@juno.ocn.ne.jp. Department of Virology, Toyama Institute of Health, Toyama, Japan. toyamaeiken3@juno.ocn.ne.jp.Department of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.Department of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.Department of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan.Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan.Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.Department of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.Department of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.Department of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.Department of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.Department of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.Department of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.Department of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

33435994

Citation

Tani, Hideki, et al. "Evaluation of SARS-CoV-2 Neutralizing Antibodies Using a Vesicular Stomatitis Virus Possessing SARS-CoV-2 Spike Protein." Virology Journal, vol. 18, no. 1, 2021, p. 16.
Tani H, Kimura M, Tan L, et al. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein. Virol J. 2021;18(1):16.
Tani, H., Kimura, M., Tan, L., Yoshida, Y., Ozawa, T., Kishi, H., Fukushi, S., Saijo, M., Sano, K., Suzuki, T., Kawasuji, H., Ueno, A., Miyajima, Y., Fukui, Y., Sakamaki, I., Yamamoto, Y., & Morinaga, Y. (2021). Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein. Virology Journal, 18(1), 16. https://doi.org/10.1186/s12985-021-01490-7
Tani H, et al. Evaluation of SARS-CoV-2 Neutralizing Antibodies Using a Vesicular Stomatitis Virus Possessing SARS-CoV-2 Spike Protein. Virol J. 2021 01 12;18(1):16. PubMed PMID: 33435994.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein. AU - Tani,Hideki, AU - Kimura,Miyuki, AU - Tan,Long, AU - Yoshida,Yoshihiro, AU - Ozawa,Tatsuhiko, AU - Kishi,Hiroyuki, AU - Fukushi,Shuetsu, AU - Saijo,Masayuki, AU - Sano,Kaori, AU - Suzuki,Tadaki, AU - Kawasuji,Hitoshi, AU - Ueno,Akitoshi, AU - Miyajima,Yuki, AU - Fukui,Yasutaka, AU - Sakamaki,Ippei, AU - Yamamoto,Yoshihiro, AU - Morinaga,Yoshitomo, Y1 - 2021/01/12/ PY - 2020/10/01/received PY - 2021/01/06/accepted PY - 2021/1/13/entrez PY - 2021/1/14/pubmed PY - 2021/1/26/medline KW - Neutralization assay KW - Pseudotyped virus KW - SARS-CoV-2 KW - Serum KW - VSV KW - Whole blood SP - 16 EP - 16 JF - Virology journal JO - Virol J VL - 18 IS - 1 N2 - BACKGROUND: SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV. SARS-CoV-2 is highly pathogenic in humans and is classified as a biosafety level (BSL)-3 pathogen, which makes manipulating it relatively difficult due to its infectious nature. METHODS: To circumvent the need for BSL-3 laboratories, an alternative assay was developed that avoids live virus and instead uses a recombinant VSV expressing luciferase and possesses the full length or truncated spike proteins of SARS-CoV-2. Furthermore, to measure SARS-CoV-2 neutralizing antibodies under BSL2 conditions, a chemiluminescence reduction neutralization test (CRNT) for SARS-CoV-2 was developed. The neutralization values of the serum samples collected from hospitalized patients with COVID-19 or SARS-CoV-2 PCR-negative donors against the pseudotyped virus infection evaluated by the CRNT were compared with antibody titers determined from an enzyme-linked immunosorbent assay (ELISA) or an immunofluorescence assay (IFA). RESULTS: The CRNT, which used whole blood collected from hospitalized patients with COVID-19, was also examined. As a result, the inhibition of pseudotyped virus infection was specifically observed in both serum and whole blood and was also correlated with the results of the IFA. CONCLUSIONS: In conclusion, the CRNT for COVID-19 is a convenient assay system that can be performed in a BSL-2 laboratory with high specificity and sensitivity for evaluating the occurrence of neutralizing antibodies against SARS-CoV-2. SN - 1743-422X UR - https://www.unboundmedicine.com/medline/citation/33435994/Evaluation_of_SARS_CoV_2_neutralizing_antibodies_using_a_vesicular_stomatitis_virus_possessing_SARS_CoV_2_spike_protein_ L2 - https://virologyj.biomedcentral.com/articles/10.1186/s12985-021-01490-7 DB - PRIME DP - Unbound Medicine ER -